Mr. Callow is the Managing Partner of Boston Millennia Partners. He was Lead Director of PAREXEL International Corp., a clinical trials management company sold on in 2017 for $5 billion. He has served as a Director of a number of other public and private companies, including ILEX Oncology, Inc., a cancer pharmaceutical company acquired by Genzyme for $1 billion; and COTA Healthcare, Inc., a precision medicine company that analyzes clinical and billing data of oncology patients. He serves as a board member at Tufts University and the Leukemia & Lymphoma Society. Mr. Callow is a graduate of Tufts University and holds an MBA from the Amos Tuck School at Dartmouth.